AI English summary of an SEC filing — figures as filed
UnitedHealth Group UNHUnitedHealth Group announced on November 18, 2025 the appointment of Scott Gottlieb, M.D. as an independent director, effective immediately. The company said Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors.
Key points
AI summaryUnitedHealth Group announced on November 18, 2025 the appointment of Scott Gottlieb, M.D. as an independent director, effective immediately. The company said Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors.
The company said Dr. Gottlieb served as FDA commissioner from 2017 to 2019 and held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee. It added that he is a physician and an elected member of the National Academy of Medicine.
UnitedHealth Group said Dr. Gottlieb serves as a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates, and also serves as a director of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc.
The company said Dr. Gottlieb will receive compensation for his services as a director in accordance with the Company's standard compensation program for non-employee directors and is entering into a standard form of indemnification agreement. UnitedHealth Group said there are no arrangements or understandings between Dr. Gottlieb and any other person pursuant to which he was appointed to the Board of Directors, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Appointment of Scott Gottlieb, M.D. as independent director
UnitedHealth Group announced on November 18, 2025 the appointment of Scott Gottlieb, M.D. as an independent director, effective immediately. The company said Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors.
Source · Based on the filing body and exhibits
Dr. Gottlieb's career as FDA commissioner and other roles
The company said Dr. Gottlieb served as FDA commissioner from 2017 to 2019 and held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee. It added that he is a physician and an elected member of the National Academy of Medicine.
Source · Based on the filing body and exhibits
Dr. Gottlieb's other directorships
UnitedHealth Group said Dr. Gottlieb serves as a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates, and also serves as a director of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc.
Source · Based on the filing body and exhibits
Director compensation and indemnification agreement terms
The company said Dr. Gottlieb will receive compensation for his services as a director in accordance with the Company's standard compensation program for non-employee directors and is entering into a standard form of indemnification agreement. UnitedHealth Group said there are no arrangements or understandings between Dr. Gottlieb and any other person pursuant to which he was appointed to the Board of Directors, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…